Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.